Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya

Matthew J. Akiyama; Lindsey R. Riback; Mercy Nyakowa; Helgar Musyoki; John A. Lizcano; Abbe Muller; Chenshu Zhang; Josephine G. Walker; Jack Stone; Peter Vickerman; Peter Cherutich; Ann E. Kurth

doi:10.1111/jvh.13662

Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya

Matthew J. Akiyama, Lindsey R. Riback, Mercy Nyakowa, Helgar Musyoki, John A. Lizcano, Abbe Muller, Chenshu Zhang, Josephine G. Walker, Jack Stone, Peter Vickerman, Peter Cherutich, Ann E. Kurth

Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	691-694
Number of pages	4
Journal	Journal of Viral Hepatitis
Volume	29
Issue number	8
DOIs	https://doi.org/10.1111/jvh.13662
State	Published - Aug 2022

Keywords

Africa
DAA
HCV
LMIC
PWID

ASJC Scopus subject areas

Hepatology
Infectious Diseases
Virology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.13662

Cite this

@article{7c63203307ff4685b0b0be203264b7e9,

title = "Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya",

keywords = "Africa, DAA, HCV, LMIC, PWID",

author = "Akiyama, {Matthew J.} and Riback, {Lindsey R.} and Mercy Nyakowa and Helgar Musyoki and Lizcano, {John A.} and Abbe Muller and Chenshu Zhang and Walker, {Josephine G.} and Jack Stone and Peter Vickerman and Peter Cherutich and Kurth, {Ann E.}",

note = "Funding Information: The project described was supported by the Grant Number R01DA032080 and R01DA032080-05S1 from the National Institute on Drug Abuse of the National Institutes of Health. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. This research was supported by the National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH) under Award Number R01DA032080 and a pilot grant from the Albert Einstein Global Health Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This project was supported by grants (numbers R01DA032080 and R01DA032080-05S1, awarded to principal investigators AEK and PC) from the National Institute on Drug Abuse (NIDA). Dr. Akiyama is also supported by grants from NIDA R00 DA043011, DP2 DA053730, and the National Institute on Minority Health and Health Disparities (NIMHD) R01MD016744. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. We gratefully acknowledge the Centers for Disease Control and Prevention, Division of Viral Hepatitis (Atlanta, GA, USA) for assistance in genotyping the specimens obtained in this study; Kenya National Blood Transfusion Services (Nairobi, Mombasa, Malindi, and Kisumu, Kenya) for assistance in plasma separation; and the Kenya Medical Research Institute (Kisumu, Kenya) for assistance with HCV RNA confirmatory tests. We also thank Martin Sirengo, Janet Muriithi, Emily Juma, and the research assistants at the National AIDS & STI Control Program for their contributions and support, as well as National Institute on Drug Abuse Project Officer Dionne Jones for her continuing support. Funding Information: The project described was supported by the Grant Number R01DA032080 and R01DA032080‐05S1 from the National Institute on Drug Abuse of the National Institutes of Health. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Funding Information: This research was supported by the National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH) under Award Number R01DA032080 and a pilot grant from the Albert Einstein Global Health Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This project was supported by grants (numbers R01DA032080 and R01DA032080‐05S1, awarded to principal investigators AEK and PC) from the National Institute on Drug Abuse (NIDA). Dr. Akiyama is also supported by grants from NIDA R00 DA043011, DP2 DA053730, and the National Institute on Minority Health and Health Disparities (NIMHD) R01MD016744. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. We gratefully acknowledge the Centers for Disease Control and Prevention, Division of Viral Hepatitis (Atlanta, GA, USA) for assistance in genotyping the specimens obtained in this study; Kenya National Blood Transfusion Services (Nairobi, Mombasa, Malindi, and Kisumu, Kenya) for assistance in plasma separation; and the Kenya Medical Research Institute (Kisumu, Kenya) for assistance with HCV RNA confirmatory tests. We also thank Martin Sirengo, Janet Muriithi, Emily Juma, and the research assistants at the National AIDS & STI Control Program for their contributions and support, as well as National Institute on Drug Abuse Project Officer Dionne Jones for her continuing support. ",

year = "2022",

month = aug,

doi = "10.1111/jvh.13662",

language = "English (US)",

volume = "29",

pages = "691--694",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya

AU - Akiyama, Matthew J.

AU - Riback, Lindsey R.

AU - Nyakowa, Mercy

AU - Musyoki, Helgar

AU - Lizcano, John A.

AU - Muller, Abbe

AU - Zhang, Chenshu

AU - Walker, Josephine G.

AU - Stone, Jack

AU - Vickerman, Peter

AU - Cherutich, Peter

AU - Kurth, Ann E.

N1 - Funding Information: The project described was supported by the Grant Number R01DA032080 and R01DA032080-05S1 from the National Institute on Drug Abuse of the National Institutes of Health. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. This research was supported by the National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH) under Award Number R01DA032080 and a pilot grant from the Albert Einstein Global Health Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This project was supported by grants (numbers R01DA032080 and R01DA032080-05S1, awarded to principal investigators AEK and PC) from the National Institute on Drug Abuse (NIDA). Dr. Akiyama is also supported by grants from NIDA R00 DA043011, DP2 DA053730, and the National Institute on Minority Health and Health Disparities (NIMHD) R01MD016744. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. We gratefully acknowledge the Centers for Disease Control and Prevention, Division of Viral Hepatitis (Atlanta, GA, USA) for assistance in genotyping the specimens obtained in this study; Kenya National Blood Transfusion Services (Nairobi, Mombasa, Malindi, and Kisumu, Kenya) for assistance in plasma separation; and the Kenya Medical Research Institute (Kisumu, Kenya) for assistance with HCV RNA confirmatory tests. We also thank Martin Sirengo, Janet Muriithi, Emily Juma, and the research assistants at the National AIDS & STI Control Program for their contributions and support, as well as National Institute on Drug Abuse Project Officer Dionne Jones for her continuing support. Funding Information: The project described was supported by the Grant Number R01DA032080 and R01DA032080‐05S1 from the National Institute on Drug Abuse of the National Institutes of Health. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Funding Information: This research was supported by the National Institute On Drug Abuse (NIDA) of the National Institutes of Health (NIH) under Award Number R01DA032080 and a pilot grant from the Albert Einstein Global Health Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This project was supported by grants (numbers R01DA032080 and R01DA032080‐05S1, awarded to principal investigators AEK and PC) from the National Institute on Drug Abuse (NIDA). Dr. Akiyama is also supported by grants from NIDA R00 DA043011, DP2 DA053730, and the National Institute on Minority Health and Health Disparities (NIMHD) R01MD016744. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health. We gratefully acknowledge the Centers for Disease Control and Prevention, Division of Viral Hepatitis (Atlanta, GA, USA) for assistance in genotyping the specimens obtained in this study; Kenya National Blood Transfusion Services (Nairobi, Mombasa, Malindi, and Kisumu, Kenya) for assistance in plasma separation; and the Kenya Medical Research Institute (Kisumu, Kenya) for assistance with HCV RNA confirmatory tests. We also thank Martin Sirengo, Janet Muriithi, Emily Juma, and the research assistants at the National AIDS & STI Control Program for their contributions and support, as well as National Institute on Drug Abuse Project Officer Dionne Jones for her continuing support.

PY - 2022/8

Y1 - 2022/8

KW - Africa

KW - DAA

KW - HCV

KW - LMIC

KW - PWID

UR - http://www.scopus.com/inward/record.url?scp=85126254824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126254824&partnerID=8YFLogxK

U2 - 10.1111/jvh.13662

DO - 10.1111/jvh.13662

M3 - Article

C2 - 35274394

AN - SCOPUS:85126254824

SN - 1352-0504

VL - 29

SP - 691

EP - 694

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - 8

ER -

Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this